CRISPR Therapeutics AG
שורט

CRSP – 30-Min Short Trade Setup !

61
📉 🔻
🔹 Asset: CRISPR Therapeutics AG (CRSP – NASDAQ)
🔹 Timeframe: 30-Min Chart
🔹 Setup Type: Bearish Pennant Breakdown + Retest Rejection

📊 Trade Plan (Short Position)
✅ Entry Zone: Below $31.30 (Confirmed Breakdown)
✅ Stop-Loss (SL): Above $33.58 (White Resistance Level)

🎯 Take Profit Targets:
📌 TP1: $28.56 (Mid-support zone)
📌 TP2: $25.61 (Key demand area)

📐 Risk-Reward Ratio Calculation
📉 Risk (SL Distance):
$33.58 - $31.30 = $2.28 risk per share
📈 Reward to TP1:
$31.30 - $28.56 = $2.74 → R/R = 1:1.20
📈 Reward to TP2:
$31.30 - $25.61 = $5.69 → R/R = 1:2.49

🔍 Technical Analysis & Strategy
📌 Bearish Pennant Breakdown: Price broke the pattern and is now rejecting the yellow zone on a retest.
📌 Lower Highs + Breakdown Structure: Indicates weakness, confirming bearish bias.
📌 Support Levels Below: Room to fall towards multiple levels of structure.
📌 Volume Check: Look for continued weak volume on bounce to confirm lack of demand.

📉 Trade Execution & Risk Management
📊 Entry Trigger: Break and hold below $31.30 with weak bullish reaction.
📉 Trailing Stop Strategy: Move SL to breakeven once TP1 is hit.
💰 Partial Profit Booking:
✔ Close 50% position at $28.56
✔ Let remaining ride toward $25.61
✔ Adjust SL to breakeven after TP1

⚠️ Setup Invalidation
❌ Strong bullish reversal candle with volume above $33.58
❌ Consolidation above yellow zone after false breakdown
❌ Positive news or catalyst reversing trend

🚨 Final Thoughts
✔ Clean breakdown pattern with confluence resistance at $33.58
✔ Bearish trend intact with lower highs and breakdowns
✔ High probability setup with strong R/R potential
💡 Stick to the plan, manage risk, and let the chart do the talking.

🔗 #CRSP #OptionsTrading #NASDAQStocks #TradingSetup #BearishTrade #ProfittoPath #SwingTradeSetup #RiskReward #ChartAnalysis #TradingView

כתב ויתור

המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.